List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

Displaying 1 - 10 of 4836 results
  1. Clinical Vector for TCR Immunotherapy Targeted to Melanoma

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase II proposal is a continuation of our Phase I award, Lentiviral Vectors for TCR Immunotherapy Targeted to Melanoma. We have successfully achieved the milestones laid out in our initial application. We generated a lentiviral gene vector capable of expressing a T cell receptor (TCR) specific for the tyrosinase:368-376 epitope, and demonstrated the act ...

    SBIR Phase II 2010 Department of Health and Human Services
  2. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

    SBC: SAVARA INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prevalence of almost in CF patients in the US This is concerning as MRSA positivity is associated with a faster decline of lung function and a years shorter median life expectancy compared to CF p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a number of developed countries, the risk of death associated with HIV-1 infection has sharply declined due to the use of highly active antiretroviral therapy (HAART). Unfortunately, the rate of new HIV i ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Additional costs related to formulation, chronic tox and general development of PTI-125

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Project Summary Abstract PTIis a novel small molecule AD therapeutic candidate with a novel target and mechanism of actionPTIbinds and reverses an altered conformation of the scaffolding protein filamin AFLNAto prevent Aandapos s tight binding to and toxic signaling via thenicotinic acetylcholine receptornAChRas well as Aandapos s aberrant activation of toll like receptorTLRHenceby restoring FLNAa ...

    SBIR Phase II 2018 Department of Health and Human Services
  5. ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial

    SBC: CELDARA MEDICAL, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The global burden of cancer doubled between 1975 and 2000. Cancer became the leading cause of death worldwide in 2010, and is projected to double again by 2020 and to triple by 2030. This horrible disease has touched each of us, and despite enormous investments in prevention and treatment, its impact continues to accelerate. Ideally, any cancer therapy should ...

    SBIR Phase II 2012 Department of Health and Human Services
  6. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human Services
  7. IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The development of Sanaria's aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoite (SPZ)-based products has received international recognition during the past year, due principally to four findings: 1)PfSPZ Challenge (infectious PfSPZ) induced malaria in volunteers, 2) PfSPZ Vaccine (radiation attenuated PfSPZ) induced unprecedented levels ...

    SBIR Phase II 2012 Department of Health and Human Services
  8. Development of RLIP76 protein as a Radiation Countermeasure

    SBC: TERAPIO            Topic: NIAID

    DESCRIPTION (provided by applicant): There remains a critical need for medicines that can counteract the toxic effects of radiation exposure. Terapio is developing a recombinant protein, RLIP76, for use as a radioprotectant for workers, military personnel, or civilians that are either in imminent danger of radiation exposure, or have already been exposed. In research carried out at the Unive ...

    SBIR Phase II 2012 Department of Health and Human Services
  9. A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTIONprovided by applicantThe world needs a highly effective malaria vaccineSanaria rPfSPZ Vaccinecomposed of asepticpurifiedcryopreserved radiation attenuated PfSPZprotectedof volunteers in an NIH clinical trialThe vaccine has been administered by direct venous inoculationDVItosubjects in MaliTanzaniaEquatorial GuineaEGand USASafetytolerabilityhigh grade protectionheterologous protection af ...

    SBIR Phase II 2016 Department of Health and Human Services
  10. TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure

    SBC: Chrysalis BioTherapeutics, Inc.            Topic: NIAID

    DESCRIPTIONprovided by applicantWith increasing risk of a nuclear accident or detonationthere is a critical need to develop effective medicinal countermeasures that can be delivered to victims after an incident to increase survival and prevent long term effects in those that surviveMajor causes of death following a nuclear incident include acute radiation syndromesARSthat destroy hematopoietic ste ...

    SBIR Phase II 2016 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government